Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (76)	6/14/2004 1:03:44 PM
From: Jibacoa	Read Replies (1) \| Respond to of 802

INGN..." lets hope that it will find support above the $5 level. Well, so far that seems to be the case, with the help of some "news".<g> 6/14/04 Introgen Therapeutics Provides Highlights of Post-ASGT - ASCO Conference Call AUSTIN, Texas, June 14 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN) announced today the highlights of a conference call conducted on June 11, 2004 to review the data presented at both the recent American Society of Gene Therapy annual meeting as well as a company-sponsored symposium at the American Society of Clinical Oncology. The call was hosted by David Nance, President and CEO and Dr. Robert E. Sobol, Introgen's Senior Vice President, Medical and Scientific Affairs. Highlights from the call included: Advexin Phase II monotherapy data in recurrent head and neck cancer compares favorably with the Erbitux data in a number of areas, including tumor growth control and survival. New pre-clinical data suggests enhanced therapeutic effects of combined Advexin and Erbitux therapies in an animal model of human non-small cell lung cancer. Phase II clinical data in breast and non-small cell lung cancer suggests enhanced clinical activity of Advexin in combination with chemotherapy and radiation. A growing body of data suggests that Advexin has clinical activity in a variety of cancer types, and the safety data from these studies suggests that this activity may be achieved without the treatment limiting side-effects frequently associated with many other cancer therapies. Advexin is well tolerated as a monotherapy. The addition of Advexin to standard chemotherapy or radiation does not appear to increase the frequency or severity of side-effects normally associated with these regimens. Joining Mr. Nance and Dr. Sobol on the call were Dr. John Nemunaitis, Medical Director, and Dr. Neil Senzer, Scientific Director, both of the Mary Crowley Medical Research Center at Baylor-Charles A. Sammons Cancer Center in Dallas and Dr. Walter Curran, Professor and Chairman, Department of Radiation Oncology, and Clinical Director of the Kimmel Cancer Center at Thomas Jefferson University, Philadelphia and Group Chair of the national cooperative Radiation Therapy Oncology Group (RTOG). These physicians are well recognized experts in the development of novel cancer therapies. corporate-ir.net